New national study into long-term health impacts of COVID-19 launched

A major UK research study into the long-term health impacts of COVID-19 on hospitalised patients, involving researchers from the University of Liverpool, has been launched.

The PHOSP-COVID study has been awarded £8.4million jointly by UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR). This study is one of a number of COVID-19 studies that have been given urgent public health research status by the Department of Health and Social Care.

Led by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, the PHOSP-COVID study will draw on expertise from a consortium of leading researchers, and clinicians from across the UK to assess the impact of COVID-19 on patient health and their recovery. Researchers from the University of Liverpool are members of this consortium.

Around 10,000 patients are expected to take part, making it the largest comprehensive study in the world to understand and improve the health of survivors after hospitalisation from COVID-19.

Health and Social Care Secretary Matt Hancock, said: “As we continue our fight against this global pandemic, we are learning more and more about the impact the disease can have not only on immediate health, but longer-term physical and mental health too.

“This world-leading study is another fantastic contribution from the UK’s world-leading life sciences and research sector. It will also help to ensure future treatment can be tailored as much as possible to the person.”

Chief Medical Officer Professor Chris Whitty, said: “As well as the immediate health impacts of the virus it is also important to look at the longer term impacts on health, which may be significant.

“We have rightly focused on mortality, and what the UK can do straight away to protect lives but we should also look at how COVID-19 impacts on the health of people after they have recovered from the immediate disease. This UKRI and NIHR funded study is one of the first steps in doing this.”

Calum Semple, Professor in Child Health and Outbreak Medicine, University of Liverpool, said: “Liverpool continues to demonstrate that it has both the skills and expertise in infection health research to make a difference globally. This research with covid-19 survivors builds on our work describing Post-Ebola Syndrome.”

“Our involvement in this new study of COVID survivors will improve our understanding of the long term consequences of this awful disease, with focus on respiratory problems and fatigue. By better understanding the causes of long-term health problems in COVID survivors, rehabilitation programs and therapeutic strategies can be developed.”

Symptoms of COVID-19 have varied among those who have tested positive: some have displayed no symptoms, while others have developed severe pneumonia and sadly even lost their lives. For those who were hospitalised and have since been discharged, it is not yet clear what the medical, psychological and rehabilitation needs for this group of patients will be to enable them to make as full a recovery as possible.

Patients on the study will be assessed using techniques such as advanced imaging, data collection and analysis of blood and lung samples, creating a comprehensive picture of the impact COVID-19 has had on longer term health outcomes across the UK.

The PHOSP-COVID team will then develop trials of new strategies for clinical care, including personalised treatments for groups of patients based on the particular disease characteristics they show as a result of having COVID-19 to improve their long term health.

UK Research and Innovation Chief Executive, Professor Ottoline Leyser, said: “We have much to learn about the long-term health impacts of COVID-19 and its management in hospital, including the effects of debilitating lung and heart conditions, fatigue, trauma and the mental health and wellbeing of patients. UKRI is collaborating with NIHR to fund one of the world’s largest studies to track the long-term effects of the virus after hospital treatment, recognising that for many people survival may be just the start of a long road to recovery. This study will support the development of better care and rehabilitation and, we hope, improve the lives of survivors.”

Professor Nishan Canagarajah, Vice-Chancellor and President of the University of Leicester, said: “The University of Leicester continues to play a world-leading role in the UK and beyond in health research. The confidence in our pioneering research and our researchers as true Citizens of Change, is recognised through the awarding of the PHOSP-COVID study. I am incredibly proud of the achievements of our researchers throughout the coronavirus pandemic who have demonstrated the power of, and importance of world-changing research to transform patient outcomes and ultimately to save lives.”

Professor Melanie Davies, Director of the NIHR Leicester Biomedical Research Centre, said: “The purpose of a Biomedical Research Centre is to translate scientific breakthroughs into benefits for patients at pace.

“The coronavirus pandemic has highlighted the value of centres like ours in Leicester where we are leading research embedded into clinical care settings, which will have a direct impact on patient care, and we are delighted to be awarded this prestigious funding to continue our exemplary record in the fight against coronavirus.”

The PHOSP-COVID study is widely supported across the NIHR infrastructure, including the Translational Research Collaborations for respiratory, mental health, cardiovascular, dementia, and diet, exercise and nutrition, and many of the NIHR Biomedical Research Centres, which are set up to translate lab-based scientific breakthroughs into potential new treatments, diagnostics and medical technologies.

/Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.